SCHEMBL27059155

SCHEMBL27059155

COC(=O)c1ccc(-c2nc(Nc3cnn(CC(F)F)c3)ncc2F)cc1F

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK8 P45983 2/20 0.45
GSK3B P49841 2/20 0.45
CAMKK2 Q96RR4 2/20 0.45
PIK3CG P48736 1/20 0.45
MAP3K14 Q99558 1/20 0.43
JAK2 O60674 5/20 0.42
KCNH2 Q12809 3/20 0.42
JAK3 P52333 3/20 0.42
CDK2 P24941 1/20 0.42
TBK1 Q9UHD2 3/20 0.41
IKBKE Q14164 1/20 0.41
CDK6 Q00534 3/20 0.41
FLT4 P35916 1/20 0.41
CSF1R P07333 2/20 0.41
CDK4 P11802 2/20 0.41
JAK1 P23458 1/20 0.41
TYK2 P29597 1/20 0.41
FLT3 P36888 1/20 0.41
BTK Q06187 1/20 0.40
STK17A Q9UEE5 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27059152 0.90 MAPK8 (0.47) MAPK8GSK3BCAMKK2PIK3CGMAP3K14
SCHEMBL22097816 0.87 JAK2 (0.45) MAP3K14JAK2KCNH2JAK3CDK2
SCHEMBL29942109 0.87 JAK2 (0.45) MAP3K14JAK2KCNH2JAK3CDK2
SCHEMBL22097953 0.86 CCNE2 (0.51) MAPK8GSK3BCAMKK2PIK3CGJAK2
SCHEMBL27447231 0.84 JAK3 (0.51) JAK2JAK3JAK1TYK2
SCHEMBL30956378 0.83 JAK3 (0.46) JAK2JAK3FLT4JAK1TYK2
SCHEMBL28919422 0.82 JAK2 (0.44) MAPK8GSK3BCAMKK2PIK3CGJAK2
SCHEMBL24853544 0.82 CDK4 (0.52) JAK2JAK3CDK2CDK6CSF1R
SCHEMBL22098005 0.80 DYRK2 (0.46) MAPK8GSK3BCAMKK2PIK3CGJAK2
SCHEMBL24853225 0.79 JAK1 (0.50) GSK3BJAK2JAK3CDK2JAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12030870-B2 Benzamides of pyrazolylamino-pyrimidinyl derivatives, and compositions and methods thereof LYNK PHARMACEUTICALS CO. LTD. (CN) 2024-07-09 US disclosed
US-20240025882-A1 BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2024-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12030870-B2 Benzamides of pyrazolylamino-pyrimidinyl derivatives, and compositions and methods thereof JAK2, JAK1, JAK3 MAPK8 728/4885GSK3B 1177/4885CAMKK2 1340/4885
US-20240025882-A1 BENZAMIDES OF PYRAZOLYLAMINO- PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF JAK2, JAK1, JAK3 MAPK8 728/4885GSK3B 1177/4885CAMKK2 1340/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.